Opinion|Videos|January 29, 2025

Biotin, Benign Modules, and Final Takeaways

Name: Chapter 4: Biotin, Benign Modules, and Final Takeaways
Uploaded: 2025-01-29T15:28:36.374Z
Duration: 2M49S
Description: Todd W. Frieze, MD, concludes this series discussing differences in benign vs cancerous tumors and key final takeaways.

Author(s)Todd W. Frieze, MD

Todd W. Frieze, MD, concludes this series discussing differences in benign vs cancerous tumors and key final takeaways.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Biotin, Benign Modules, and Final Takeaways

Newsletter

Latest CME

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

22nd Annual Meeting of the International Society of Gastrointestinal Oncology

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Nevada

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Evolving Treatment Paradigms for Patients With Hemoglobinopathies

“D” Is for Diagnosis: Decoding a Difficult Thoracic Malignancy – Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

23rd Annual Winter Lung Cancer Conference®

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Cases and Conversations™: The Rationale for Utilizing Nonfactor Replacement Therapies in Hemophilia Care

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Molecular Testing and Personalized Strategies in Pancreatic Cancer: Targeting NRG1 and Rare Drivers With an Optimized Approach

Optimizing Care for Patients With Tardive Dyskinesia

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Community Practice Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice?

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

43rd Annual Miami Breast Cancer Conference®

‘REEL’ Time Patient Counseling™: Improving Quality of Life for Patients with Sickle Cell Disease – Disease Modifying Therapy Vs. Curative Approaches

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

19th Annual New York GU Cancers Congress™

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Cases and Conversations™: Redefining Treatment Pathways in Low-Grade Serous Ovarian Cancer

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria